States have targeted co-pay accumulators, claiming they run up costs for patients who need expensive specialty drugs. Here’s why their legislation hasn’t yet had the intended impact.
ZDoggMD is redefining the scope and tone of physician influence on social media
Experts predict the controversial tactic will be deployed far more widely this year, significantly impacting manufacturers — and, whether or not they realize it yet, patients.
How to lower drug prices in the U.S.? Lots of suggestions, few viable solutions